Fibrillary apolipoprotein e (APOE) for use in a method of treatment and / or prevention of a neurodegenerative disease
Fibrillary ApoE, especially fibrillary recombinant human ApoE4, is used to induce an immune response and produce antibodies targeting neurodegenerative diseases, effectively addressing the underlying mechanisms of diseases like Alzheimer's, halting or reversing their progression.
Patent Information
- Application Number
- PCT/EP2025/071093
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-22
- Filing Date
- 2025-07-22
- Publication Date
- 2026-01-29
AI Technical Summary
Current treatments for neurodegenerative diseases like Alzheimer's disease primarily offer symptomatic relief and do not halt or reverse the disease's progression, highlighting the need for innovative therapies that target the underlying mechanisms of the disease.
The use of fibrillary Apolipoprotein E (ApoE), particularly fibrillary recombinant human ApoE4, as a therapeutic agent, which can be administered to induce an immune response and produce antibodies specifically binding to fibrillary ApoE, thereby targeting the underlying mechanisms of neurodegenerative diseases.
This approach potentially halts or reverses the progression of neurodegenerative diseases by addressing the root causes of neuronal degeneration and amyloid plaque accumulation, offering a novel means for effective treatment and prevention.